Loading...
CINGW
XNAS
Market cap67mUSD
Nov 20, Last price  
0.00USD
1D
-5.26%
1Q
-60.44%
IPO
-99.64%
Name

Cingulate Inc

Chart & performance

D1W1MN
XNAS:CINGW chart
Exercise price
Share price
4.51
Intrinsic value
Premium
Underlying
CINGXNAS
Exercisable
Expiry

Warrant terms

Terms

Kind
Underlying share
CING (company's common)
Shares per warrant
Exercise price

Dates

Issue date
Exercisable from
Expiry

Documents

424B4 Prospectus, Dec 09, 2021 terms
8-A12B Exchange registration of securities, Dec 03, 2021 terms

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.

Key people

Shane Schaffer
Chief Executive Officer · since 2025
Chairman of the Board · since 2025
Jennifer Callahan
Chief Financial Officer · since 2025
Matthew Brams
Co-Founder, Executive Vice President, Chief Medical Officer · since 2018
Raul Silva
Co-Founder, Executive Vice President, Chief Science Officer · since 2018
Nilay Patel
Chief Legal Officer · since 2025
Peter Werth
Director · since 2022
Independent Director · since 2024
Bryan Lawrence
Independent Director · since 2024
IPO date
Oct 07, 2021
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT